Načítá se...
Rufinamide-Loaded Chitosan Nanoparticles in Xyloglucan-Based Thermoresponsive In Situ Gel for Direct Nose to Brain Delivery
In 2004, the US FDA approved Rufinamide, an anti-epileptic drug under the brand name Banzel(®). In 2015, Banzel(®) received approval for its use in pediatric patients (ages 1–4 years). Rufinamide shows low oral bioavailability due to a low dissolution rate resulting in less of the drug reaching the...
Uloženo v:
| Vydáno v: | Front Pharmacol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8257053/ https://ncbi.nlm.nih.gov/pubmed/34234679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.691936 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|